Back
Edge
StocktwitsEarnings
Official STOCKTWITS Representative
symbol logo$BMRN Q2 '26 Earnings Results & Recap • Reported GAAP EPS of $0.23 down -81.60% YoY • Reported revenue of $989.71M up 19.91% YoY • BioMarin Pharmaceutical Inc. raised its full-year 2026 total revenue guidance to a range of $3.875 billion to $3.925 billion, with VOXZOGO revenue expected to reach at least $1 billion in 2026.

Price since post

Full Details

Advertisement|Remove ads.